Clinical Trials Logo

Metastatic Cervical Cancer clinical trials

View clinical trials related to Metastatic Cervical Cancer.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT04230954 Terminated - Cervical Cancer Clinical Trials

Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer

Start date: April 16, 2020
Phase: Phase 2
Study type: Interventional

Drug: Cabozantinib Drug: Pembrolizumab

NCT ID: NCT03786107 Terminated - Clinical trials for Metastatic Cervical Cancer

HER-Seq: A Blood-based Screening Study to Identify Patients With HER2 Mutations for Enrollment Into Clinical Research Studies of Neratinib

Start date: March 14, 2019
Phase:
Study type: Observational

This is a multi-center, observational genomic screening protocol to identify participants whose tumors harbor somatic mutations in the ERBB2 (HER2) gene, as measured in circulating tumor DNA (ctDNA) . Participants with histologically confirmed, hormone receptor positive, HER-2 negative, metastatic breast cancer (MBC) or metastatic cervical cancer (MCC) are eligible for screening at 6 months intervals, or if disease progression is suspected/confirmed. Blood samples will be collected from eligible participants and ctDNA will be extracted and sequenced at a central laboratory, using a HER2-targeted next generation sequencing (NGS) test. A certified molecular test report will be issued from the central laboratory and provided to the investigators and the study sponsor. Participants who are identified with HER2 mutations by this screening protocol will subsequently have access to an appropriate neratinib treatment protocol, pending medical eligibility.

NCT ID: NCT03277482 Terminated - Clinical trials for Recurrent Ovarian Carcinoma

Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer

Start date: June 1, 2018
Phase: Phase 1
Study type: Interventional

This research study is evaluating the safety and effectiveness of 2 immunotherapy drugs in combination with radiation therapy as a possible treatment for recurrent or metastatic gynecologic cancer. The names of the immunotherapy drugs involved in this study are: - Durvalumab - Tremelimumab